高级检索
当前位置: 首页 > 详情页

Calcium dobesilate-induced hyperpyrexia: A case report

Calcium dobesilate-induced hyperpyrexia A case report

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. [2]Department of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, 650032.
出处:
ISSN:

关键词: calcium dobesilate case report fever misdiagnosis treatment

摘要:
Calcium dobesilate, a vasoprotective and antioxidant agent, is gradually being used for the treatment of chronic kidney disease. Calcium dobesilate-induced hyperpyrexia is a rare clinical event, and few studies have reported it.The patient took calcium dobesilate, which caused high fever. After stopping calcium dobesilate, his body temperature returned to normal.Based on the medical history, symptoms and signs, the patient was diagnosed with drug fever caused by calcium dobesilate.Calcium dobesilate was stopped, and supportive treatment was given at the same time.The present case was initially misdiagnosed as a fever caused by a bacterial infection, but treatment with the antibiotic moxifloxacin was ineffective. Based on the patient's medical history, laboratory and examination results, body temperature changes, and Naranjo Advanced Drug Response Scale, calcium dobesilate-induced hyperpyrexia was diagnosed. After discontinuation of calcium dobesilate, the patient's body temperature normalized, and no additional episode of fever was observed at follow-up.Moreover, misdiagnosis and mistreatment of this condition can deteriorate the patient's condition. Herein, we report a case of calcium dobesilate-induced hyperpyrexia that occurred during the treatment of chronic renal insufficiency. Subsequently, a systematic analysis of the patient's diagnosis and treatment was reviewed. If unexplained high fever develops during the use of calcium dobesilate, calcium dobesilate-induced hyperpyrexia should be considered. Accordingly, calcium dobesilate should be discontinued.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
共同第一作者:
通讯作者:
通讯机构: [2]Department of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, 650032. [*1]Department of Emergency, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Wuhua District, Kunming 650032, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59119 今日访问量:1 总访问量:1876 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)